InnovAtlasMalaria No More
Research institution

University of Illinois Chicago — Carlier Lab, Department of Pharmaceutical Sciences, Retzky College of Pharmacy

Develop

University of Illinois Chicago researchers in the Carlier Lab are developing new antimalarial drug candidates designed to overcome drug resistance and target difficult-to-kill malaria parasites.

0
Endemic countries
1
U.S. states
3
Products and programs
About

What they do

University of Illinois Chicago researchers in the Carlier Lab are developing new antimalarial drug candidates designed to overcome drug resistance and target difficult-to-kill malaria parasites.1,2 PRC1910 and related antimalarial compounds were jointly developed with Dr. Maria B.2 Cassera and collaborators at the University of Georgia.2 PRC1910 cured malaria infection in mice after a single oral dose, killed both actively growing and artemisinin-induced dormant blood-stage parasites, and showed a high barrier to the development of resistance.2 U.S. R&D for the Carlier Lab is based in Chicago, Illinois.2 The work is in the development stage, with PRC1910 undergoing continued preclinical optimization.2

In the United States
Products and programs

In the field and in development

PRC1910, lead imidazo[4,5-c]pyridine-6-carboxamide antimalarial candidate1,2
Imidazo[4,5-c]pyridine-6-carboxamide antimalarial series4,2
NIH/NIAID grant 2R01AI157445, “Development of Irresistible Blood Stage Antimalarials”5,2
Where they work

Partnerships

No endemic-country partnerships are listed.

U.S. partners

Who they work with in the United States

Sources

Where this comes from

  1. 1today.uic.edu
  2. 2Confirmed by the organization
  3. 3chem.uic.edu
  4. 4newswise.com
  5. 5reporter.nih.gov